|
160 |
What are the Requirements for the Manufacture of Solid Dosage Forms in Pharmaceutical Production?
|
관리자 |
2026-08-04 |
174 |
|
159 |
The Relationship between Commissioning, Classification and Qualification in GMP Cleanrooms
|
관리자 |
2026-08-04 |
179 |
|
158 |
What are the GMP Requirements for Sterile Production according to Annex 1?
|
관리자 |
2026-08-04 |
158 |
|
157 |
What Biopharma Often Overlooks In A Scheduled Shutdown
|
관리자 |
2026-07-08 |
533 |
|
156 |
Achieving Annex 1 Compliance In Sterile Manufacturing, Part 1: Common Compliance Failures
|
관리자 |
2026-07-08 |
493 |
|
155 |
What are the Requirements for Testing for Impurities in the Pharmaceutical Industry?
|
관리자 |
2026-07-08 |
327 |
|
154 |
Why Isolators Do Not Automatically Ensure Annex 1 Compliance
|
관리자 |
2026-06-05 |
507 |
|
153 |
How Are Service Providers Qualified in a GDP Environment?
|
관리자 |
2026-06-05 |
475 |
|
152 |
CAPA and Root Cause Analysis - why FDA keeps calling them out
|
관리자 |
2026-06-05 |
472 |
|
151 |
Which GMP Requirements Apply to Stability Studies in the Pharmaceutical Industry?
|
관리자 |
2026-05-06 |
844 |
